Sign In
Buy BXRX
$0.0218
+0 (+0%)
At Close: May 28, 2024
Baudax Bio Announces $12 Million Offering Priced at a Premium to Market
08:00am, Monday, 23'rd Nov 2020
MALVERN, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today
Baudax Bio Announces Publication of ANJESO® Network Meta-Analysis in the Peer-Reviewed Journal BMC Anesthesiology
07:00am, Friday, 20'th Nov 2020
ANJESO Found to Provide Superior Pain Relief with Similar or Better Safety Compared to Other Approved IV Non-Opioid Analgesics ANJESO Found to Provide Superior Pain Relief with Similar or Better Safet
Baudax Bio, Inc. (BXRX) CEO Gerri Henwood on Q3 2020 Results - Earnings Call Transcript
02:02pm, Monday, 09'th Nov 2020
Baudax Bio, Inc. (BXRX) CEO Gerri Henwood on Q3 2020 Results - Earnings Call Transcript
Baudax Bio, Inc.'s (BXRX) CEO Gerri Henwood on Q3 2020 Results - Earnings Call Transcript
10:41am, Monday, 09'th Nov 2020
Baudax Bio, Inc.'s (BXRX) CEO Gerri Henwood on Q3 2020 Results - Earnings Call Transcript
Baudax Bio: Why I'm Catching This Falling Knife
01:24am, Tuesday, 03'rd Nov 2020
BXRX has been pummeled since the start of the pandemic dropping from the high $7s to the low $1s. In this article, I review the company developments, both negative and positive, that have transpired d
Baudax Bio to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020
07:05am, Monday, 02'nd Nov 2020
MALVERN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it will report third quar
Baudax Bio: Discounted Despite Long-Term Prospects
10:36am, Tuesday, 01'st Sep 2020
Baudax Bio recently launched their meloxicam injection product, ANJESO, for adults for the management of moderate-to-severe pain, alone or in combination with other non-NSAID analgesics.
Baudax Bio, Inc. (NASDAQ:BXRX): Is Breakeven Near?
04:28pm, Monday, 17'th Aug 2020
Baudax Bio, Inc. (NASDAQ:BXRX) is possibly approaching a major achievement in its business, so we would like to shine...
Baudax Bio Reports Second Quarter 2020 Financial Results
11:15am, Monday, 10'th Aug 2020
Commenced Commercial Launch of ANJESO® in the U.S. Awarded J-Code from CMS Executed Contract with a top National GPO for hospital purchases, Vizient, and one of the top 3 IDNs Nationally Secured $50
Baudax Bio to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020
08:05pm, Thursday, 06'th Aug 2020
MALVERN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it will report second qua
Baudax Bio Secures Permanent J-Code (J1738) for ANJESO® from Centers for Medicare and Medicaid Services
11:00am, Thursday, 06'th Aug 2020
Effective October 1, 2020, New Code Expected to Expand ReimbursementMALVERN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for
Baudax Bio (NASDAQ:BXRX) Short Interest Update
03:22am, Tuesday, 04'th Aug 2020
Baudax Bio (NASDAQ:BXRX) was the recipient of a large drop in short interest during the month of July. As of July 15th, there was short interest totalling 2,230,000 shares, a drop of 13.9% from the Ju
Virtual Presentation Highlights New ANJESO Clinical Results, Including Safety, Reductions in Opioid Use and Time to Bowel Function Recovery Data When Administered Preoperatively Prior to Colorectal Su
Baudax Bio Secures Pharmacy Supplier Agreement with Vizient Inc. for ANJESO®
11:00am, Monday, 20'th Jul 2020
MALVERN, Pa., July 20, 2020 -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has entered.
Hedge Funds Keep Buying Baudax Bio, Inc. (BXRX)
06:53pm, Sunday, 05'th Jul 2020
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filin
